178 related articles for article (PubMed ID: 21552499)
1. Effects of apelin and vascular endothelial growth factor on central retinal vein occlusion in monkey eyes intravitreally injected with bevacizumab: a preliminary study.
Zhao T; Lu Q; Tao Y; Liang XY; Wang K; Jiang YR
Mol Vis; 2011 Apr; 17():1044-55. PubMed ID: 21552499
[TBL] [Abstract][Full Text] [Related]
2. Effect of intravitreal anti-vascular endothelial growth factor treatment on the retinal gene expression in acute experimental central retinal vein occlusion.
Drechsler F; Köferl P; Hollborn M; Wiedemann P; Bringmann A; Kohen L; Rehak M
Ophthalmic Res; 2012; 47(3):157-62. PubMed ID: 22116547
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab (Avastin) as a treatment of the neovascular complications of laser-induced chorioretinal anastomosis for nonischaemic central retinal vein occlusion.
Fong KC; Barry C; McAllister IL
Clin Exp Ophthalmol; 2009 Jul; 37(5):485-9. PubMed ID: 19624345
[TBL] [Abstract][Full Text] [Related]
4. Apelin in epiretinal fibrovascular membranes of patients with retinopathy of prematurity and the changes after intravitreal bevacizumab.
Zhang Y; Jiang YR; Lu Q; Yin H; Tao Y
Retina; 2013 Mar; 33(3):613-20. PubMed ID: 23296045
[TBL] [Abstract][Full Text] [Related]
5. YC-1 Inhibits VEGF and Inflammatory Mediators Expression on Experimental Central Retinal Vein Occlusion in Rhesus Monkey.
Yan Z; An J; Shang Q; Zhou N; Ma J
Curr Eye Res; 2018 Apr; 43(4):526-533. PubMed ID: 29364731
[TBL] [Abstract][Full Text] [Related]
6. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy.
Qian J; Lu Q; Tao Y; Jiang YR
Retina; 2011 Jan; 31(1):161-8. PubMed ID: 20890241
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion.
Hoeh AE; Ach T; Schaal KB; Scheuerle AF; Dithmar S
Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1635-41. PubMed ID: 19633982
[TBL] [Abstract][Full Text] [Related]
8. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab.
Funk M; Kriechbaum K; Prager F; Benesch T; Georgopoulos M; Zlabinger GJ; Schmidt-Erfurth U
Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1025-32. PubMed ID: 19060280
[TBL] [Abstract][Full Text] [Related]
9. Three intravitreal bevacizumab versus two intravitreal triamcinolone injections in recent onset central retinal vein occlusion.
Ramezani A; Esfandiari H; Entezari M; Moradian S; Soheilian M; Dehsarvi B; Yaseri M
Acta Ophthalmol; 2014 Nov; 92(7):e530-9. PubMed ID: 24373344
[TBL] [Abstract][Full Text] [Related]
10. Serum concentration of bevacizumab after intravitreal injection in experimental branch retinal vein occlusion.
Chuang LH; Wu WC; Yeung L; Wang NK; Hwang YS; Chen KJ; Kuo JZ; Lai CC
Ophthalmic Res; 2011; 45(1):31-5. PubMed ID: 20714188
[TBL] [Abstract][Full Text] [Related]
11. Cytokine Kinetics after Monthly Intravitreal Bevacizumab for Retinal Vein Occlusion Associated with Macular Oedema.
Noma H; Mimura T; Yasuda K; Shimura M
Ophthalmic Res; 2016; 56(4):207-214. PubMed ID: 27160159
[TBL] [Abstract][Full Text] [Related]
12. Electroretinograms and level of aqueous vascular endothelial growth factor in eyes with hemicentral retinal vein occlusion or branch retinal vein occlusion.
Yasuda S; Kachi S; Ueno S; Ushida H; Piao CH; Kondo M; Terasaki H
Jpn J Ophthalmol; 2014 May; 58(3):232-6. PubMed ID: 24668132
[TBL] [Abstract][Full Text] [Related]
13. Six-month changes in cytokine levels after intravitreal bevacizumab injection for diabetic macular oedema and macular oedema due to central retinal vein occlusion.
Wen J; Jiang Y; Zheng X; Zhou Y
Br J Ophthalmol; 2015 Oct; 99(10):1334-40. PubMed ID: 25841235
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion.
Koss MJ; Pfister M; Rothweiler F; Michaelis M; Cinatl J; Schubert R; Koch FH
Acta Ophthalmol; 2012 Mar; 90(2):e98-e103. PubMed ID: 22066978
[TBL] [Abstract][Full Text] [Related]
16. Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central retinal vein occlusion (CRVO) with macular edema: a pilot study.
Shah NJ; Shah UN
Eye (Lond); 2011 Feb; 25(2):239-44. PubMed ID: 21307880
[TBL] [Abstract][Full Text] [Related]
17. Changes of aqueous vascular endothelial growth factor and pigment epithelium-derived factor following intravitreal bevacizumab for macular oedema secondary to branch retinal vein occlusion.
Park SP; Ahn JK
Clin Exp Ophthalmol; 2009 Jul; 37(5):490-5. PubMed ID: 19624346
[TBL] [Abstract][Full Text] [Related]
18. Early bevacizumab treatment of central retinal vein occlusion.
Ferrara DC; Koizumi H; Spaide RF
Am J Ophthalmol; 2007 Dec; 144(6):864-71. PubMed ID: 17916320
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical localisation of intravitreally injected bevacizumab at the posterior pole of the primate eye: implication for the treatment of retinal vein occlusion.
Julien S; Heiduschka P; Hofmeister S; Schraermeyer U
Br J Ophthalmol; 2008 Oct; 92(10):1424-8. PubMed ID: 18815425
[TBL] [Abstract][Full Text] [Related]
20. In vitro induction of protein complexes between bevacizumab, VEGF-A¹⁶⁵ and heparin: explanation for deposits observed on endothelial veins in monkey eyes.
Julien S; Biesemeier A; Schraermeyer U
Br J Ophthalmol; 2013 Apr; 97(4):511-7. PubMed ID: 23355530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
